What's new?

Sofinnova Partners Announces Sale of Corvidia Therapeutics to Novo Nordisk

Novo Nordisk acquires Corvidia for $2.1B with an upfront payment of $725M in cash   Sofinnova Partners co-founded Corvidia as its sole seed financial investor in 2015 with serial entrepreneur Michael Davidson   PARIS, France – June 11, 2020 - Sofinnova Partners, a leading European life sciences venture capital firm...

Gensight Biologics Successfully Raises €25 Million in an Oversubscribed Private Placement With Us and European Institutional Investors

October 22, 2020 12:30 AM Eastern Daylight Time   PARIS--BUSINESS WIRE --Regulatory News: GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (the "Company"), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative di...

CinCor Pharma Announces First Patient Dosed with CIN-107 in Phase 2 Study in Treatment Resistant Hypertensive Subjects

CINCINNATI, Oct. 20, 2020 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”), a clinical-stage biopharmaceutical company developing medications targeting cardiovascular disease, announced today that they have dosed the first subject in the brigHTN study. The brigHTN study is a Phase 2 clinical trial evaluating the ...

Dr. Joe Anderson Joins Sofinnova Partners

Dr. Anderson’s appointment as Partner in the Crossover Fund reflects the venture capital firm’s continuing expansion across the entire value chain of life sciences investments, from seed to later-stage   PARIS, France – October 14, 2020 - Sofinnova Partners, a leading European life sciences venture capital firm bas...

Inventiva receives FDA Breakthrough Therapy designation for lead drug candidate lanifibranor in NASH

Designation based on positive topline results from NATIVE Phase IIb clinical trial evaluating lanifibranor in non-alcoholic steatohepatitis (NASH) Lanifibranor believed to be the first drug candidate to receive Breakthrough Therapy designation in NASH since 2015 There are currently no FDA-approved treatments for th...

AFYREN appoints Stefan Borgas as Chairman of the Board

Paris, October 9th, 2020 - AFYREN, a biotechnology company producing bio-based ingredients and molecules for markets including cosmetics, food, feed, and fine chemicals, is pleased to announce the appointment of Stefan BORGAS as Chairman of its Board of Directors.   The appointment marks a key part of a strategic d...

ProQR Appoints Naveed Shams, MD, PhD as Chief Scientific Officer

Proven leader with deep worldwide ophthalmology experience, including multiple approvals globally   LEIDEN, Netherlands & CAMBRIDGE, Mass., Oct. 05, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA thera...

The European House – Ambrosetti and Sofinnova Partners announce the hosting of BioEquity Europe 2022 in Milan, Italy

For the first time, this event, which has been bringing together leading global VCs and biotech startups for over 20 years will be hosted in Milan.   Milan, Italy, October 1, 2020   The European House - Ambrosetti and Sofinnova Partners are pleased to announce that the city of Milan has been selected to host BioEqu...

Biotalys awarded €1.1 million VLAIO research grant

Non-dilutive funding to support development of novel biocontrol against bacterial plant diseases   October 01, 2020 02:00 ET Source: Biotalys   GHENT, Belgium, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Biotalys NV, a transformative food and crop protection company, today announced that it has been awarded a €1.1 million re...

RefleXion and Sofinnova Partners recognized with Salus Excellence Award at the Convergence in Oncology Summit

LAUSANNE, SWITZERLAND / AGILITYPR.NEWS / September 25, 2020 / RefleXion and Sofinnova Partners received the “Salus Partner Excellence in HealthTech Award” at the Convergence in Oncology Summit in Lausanne, Switzerland. The prize recognizes RefleXion and Sofinnova Partner’s vision and excellence in developing the di...

Sensorion successfully raises approximately €31(US$ 36.5) million in an oversubscribed private placement to US and European investors

Montpellier, September 18, 2020 – Sensorion (FR0012596468 – ALSEN – the “Company”) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders announces today the success of its previously announce...

1 2 3 ... 181